.gif)
The Committee adopted by consensus a positive opinion for an initial marketing authorisation application for Neptra, from Bayer Animal Health GmbH, a new product for the treatment of canine otitis externa caused by susceptible strains of bacteria sensitive to florfenicol and fungi sensitive to terbinafine.
The Committee adopted by consensus a positive opinion for an initial marketing authorisation application for Mirataz, from Aniserve GmbH, a new product for bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.
The Committee adopted by consensus positive opinions for type II variation applications for Exzolt and for Suvaxyn Circo and Suvaxyn Circo+MH RTU (subject to a worksharing procedure), both concerning quality changes.
The Committee also adopted by consensus a positive opinion for a type IB variation application (subject to a worksharing procedure) for Meloxidolor, Novaquin, Sedadex and Prevomax, concerning a new pharmacovigilance system.
Subscribe to PharmaTutor News Alerts by Email
